Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections

British Journal of Haematology

Volumn 103, Issue 1, 1998, Pages 205-212

  Leenders, Alexander C A P ^a,g   Daenen, Simon ^b   Jansen, Rob L H ^c   Hop, Wim C J ^a   Lowenberg, Bob ^a   Wijermans, Pierre W ^d   Cornelissen, Jan ^a   Herbrecht, Raoul ^e   Van Der Lelie, Hans ^f   Hoogsteden, Henk C ^a   Verbrugh, Henri A ^a   De Marie, Siem ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LEYENBURG HOSPITAL   (Netherlands)

^e HÔPITAL DE HAUTEPIERRE   (France)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

AmBisome; Aspergillosis; Liposomal amphotericin; Neutropenia; Randomized trial

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

ADULT; AGED; ANTIFUNGAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; FEVER; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; DEOXYCHOLIC ACID; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOSES; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 7844233666     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00944.x     Document Type: Article

References (24)

1. Anaissie, E.J., Darouiche, R.O., Abi-Said, D., Uzun, O., Mera, J., Gentry, L., Williams, T., Kontoyiannis, D.P., Karl, C.L. & Bodey, G.P. (1996) Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of literature. Clinical Infectious Diseases, 23, 964-972.
2. Bratjburg, J. & Bolard, J. (1996) Carrier effects on biological activity of amphotericin B. Clinical Microbiology Reviews, 9, 512-531.
3. Cox, D.R. (1972) Regression models and life-tables. Journal of the Royal Statistical Society B. 34, 187-220.
4. de Marie, S., Janknegt, R. & Bakker-Woudenberg, I.A.J.M. (1994) Clinical use of liposomal and lipid-complexed amphoteriein B. Journal of Antimicrobial Chemotherapy, 33, 907-916.
5. Denning, D.W. (1996a) Therapeutic outcome in invasive aspergillosis. Clinical Infectious Diseases, 25, 608-615.
6. Denning, D.W. (1996b) Diagnosis and management of invasive aspergillosis. Current Clinical Topics in Infectious Diseases, 16, 277-299.
7. Denning, D.W. & Stevens, D.A. (1990) Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Reviews in Infectious Diseases, 12, 1149-1201.
8. Dixon, W.J. (ed.) (1990) BMDP Statistical Software Manual, BMDP-5V, pp. 1207-1244. University of California Press.
9. Janknegt, R., De Marie, S., Bakker-Woudenberg, I.A.J.M. & Crommelin, D.J.A. (1992) Liposomal and lipid formulations of amphoteriein B: clinical pharmacokinetics. Clinical Pharmakinetics, 23, 279-291.
10. Karp, J.E., Burch, P.A. & Merz, W.G. (1988) An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis. American Journal of Medicine, 85, 203-208.
11. Leenders, A.C.A.P. & de Marie, S. (1996) The use of lipid formulations of amphotericin B for systemic fungal infections. Leukemia, 10, 1570-1575.
12. Leenders, A.C.A.P., Reiss, H. Portegies, P., Clezy, K., Hop, W.C.J., Hoy, J., Borleffs, J.C.C., Allworth, T., Kauffman, R.H., Jones, P., Kroon, F.P., Verbrugh, H.A. & Marie, S. (1997) Liposomal amphotericin B (AmBisome) compared with amphotericin B both following by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS, 11, 1463-1471.
13. Leenders, A.C.A.P. ten Kate, M.T., Bakker-Woudenberg, I.A.J.M. & De Marie, S. (1996) AmBisome reduces dissemination of infection in a rat-model for one-sided pulmonary aspergillosis. Journal of Antimicrobial Chemotherapy, 38, 215-225.
14. Lortholary, O., Tod, M., Rizzo, N., Padoin, C., Biard, O., Casassus, P., Guillevin, L. & Petitjean, O. (1996) Population pharmocokinetics study of teicoplanin in severely neutropenic patients. Antimicrobial Agents and Chemotherapy, 40, 1242-1247.
15. Mehta, C.R. & Patel, H. (1993) Exact Logistic Regression. CTYEL Software Corporation, Cambridge.
16. Meunier, F., Aoun, M. & Bitar, N. (1992) Candidemia in immunocompromised patients. Clinics in Infectious Diseases, 14. (Suppl. 1), S120-S125.
17. Prentice, A.G., Warnock, D.W., Johnson, S.A., Phillips, M.J. & Oliver, D.A. (1994) Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. Journal of Antimicrobial Agents and Chemotherapy 34, 247-252.
18. Prentice, H.G., Hann, I.M., Herbrecht, R., Aoun, M., Kvaloy, S., Catovsky, D., Pinkerton, C.R., Schey, S.A., Jacobs, F., Oakhill, A., Stevens, R.F. Darbyshire, P.J. & Gibson, B.E.W. (1997) A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. British Journal of Haematology 98, 711-718.
19. Ruchlemer, R., Yinnon, A.M. & Hershko, C. (1996) Changes in the natural history of invasive pulmonary aspergillosis in neutropenic leukaemic patients. Israel Journal of Medical Science, 32, 1089-1092.
20. Storm, G. & van Etten, E. (1997) Biopharmaceutical aspects of lipid formulations of amphotericin B. European Journal of Clinical Microbiology and Infectious Diseases, 16, 64-73.
21. van Ettern, E., van den Heuvel de Groot, C. & Bakker-Woudenberg, I.A.J.M. (1993) Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leukopenic mice. Journal of Antimicrobial Chemotherapy 32, 723-739.
22. Van't Wout, J.W., Novakova, I., Verhagen, C.A.H., Fibbe, W.E., de Pauw, B.E. & van der Meer, J.W.M. (1991) The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomized comparative study with amphotericin B, Journal of Infections, 22, 45-52.
23. Wingard, J.R. (1994) Infections due to resistant Candida species in patients with cancer who are receiving chemotherapy. Clinics in Infections Diseases, 19, (Suppl. 1), S49-S53.
24. Wingard, J.R. (1995) Importance of Candida species other than C. albicans as pathogens in oncology patients. Clinics in Infectious Diseases, 20, 115-125.